Published in Cardiovascular Business Week, April 26th, 2005
The financing was led by Accelerated Technologies, Inc. (ATI), a cardiovascular device accelerator that utilizes a unique combination of physician luminaries and venture capital investors to accelerate early stage companies on their path to market. Oxford Biosciences of Boston, ABN Amro Capital of the Netherlands, and Israel's Giza Venture Capital invested $9.1 million. Existing Pathway shareholders contributed the other $1 million of the investment.
Pathway Medical is developing proprietary, catheter-based products for minimally invasive treatment of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.